Skip to main content

Table 2 Clinicopathologic characteristics of patients for entire series and from first (1999–2008) and second (2009–2018) period

From: Primary localized retroperitoneal sarcomas: report from Slovenian sarcoma referral center

Characteristic All patients, n = 89 First period, n = 41 Second period, n = 48 p
Gender     0.833
 Male 47 (52.8%) 21 (51.2%) 26 (54.2%)  
 Female 42 (47.2%) 20 (48.8%) 22 (45.8%)  
Age, median (years) 62 (range 24–84) 64 (range 31–82) 62 (range 24–84) 0.922
ASA score     0.108
 1 17 (19.1%) 11 (26.8%) 6 (12.5%)  
 2 43 (48.3%) 17 (41.5%) 26 (54.2%)  
 3 22 (24.7%) 9 (22.0%) 13 (27.1%)  
 4 4 (4.5%) 1 (2.4%) 3 (6.3%)  
 Unknown 3 (3.4%) 3 (7.3%) 0  
Histologic subtype     0.424
 Dedifferentiated liposarcoma 34 (38.2%) 14 (34.1%) 20 (41.7%)  
 Well-differentiated liposarcoma 19 (21.3%) 12 (29.3%) 7 (14.6%)  
 Leiomyosarcoma 14 (15.7%) 7 (17.1%) 7 (14.6%)  
 Solitary fibrous tumor 8 (9.0%) 3 (7.3%) 5 (10.4%)  
 Malignant peripheral nerve sheath tumor 2 (2.2%) 0 2 (4.2%)  
 Other 12 (13.5%) 5 (12.2%) 7 (14.6%)  
FNCLCC Grade     0.054
 I 31 (34.8%) 21 (51.2%) 10 (20.8%)  
 II 16 (18.0%) 5 (12.2%) 11 (22.9%)  
 III 30 (33.7%) 13 (31.7%) 17 (35.4%)  
 Unknown 12 (13.5%) 2 (4.9%) 10 (20.8%)  
Median tumor size (cm) 21 (range 3–80) 24 (range 7–80) 19.5 (range 3–58) 0.403
Radiotherapy     
 Neoadjuvant 4 (4.5%) 0 4 (8.3%) 0.059
 Adjuvant 7 (7.9%) 5 (12.2%) 2 (4.2%) 0.241
Chemotherapy     
 Neoadjuvant 2 (2.2%) 1 (2.4%) 1 (2.1%) 1.0
 Adjuvant 2 (2.2%) 2 (4.9%) 0 0.209
Surgical resection margin     0.044
 R0 68 (76.4%) 27 (65.9%) 41 (85.4%)  
 R1 21 (23.6%) 14 (34.1%) 7 (14.6%)  
 R2 0 0 0  
Median time to treatment (days) 27.0 (range 0–181) 16.0 (range 0–65) 35.0 (range 4–181) < 0.001
Median weight of the specimen (g) 2259 (range 12–32,600) 3450 (range 86–32,600) 2006 (range 12–13,000) 0.087
Stage (AJCC 8th edition)     0.166
 1A 1 (1.1%) 0 1 (2.1%)  
 1B 42 (47.2%) 23 (56.1%) 19 (39.6%)  
 3A 7 (7.9%) 1 (2.4%) 6 (12.5%)  
 3B 39 (43.8%) 17 (41.5%) 22 (45.8%)  
Median surgery duration (hours) 7.3 (range 1.3–19.0) 7.5 (range 2–14.5) 7.0 (range 1.3–19) 0.669
Median blood loss (l) 1.0 (range minimal–32) 0.8 (range minimal–32) 1.4 (range minimal–30) 0.853
Resection type     0.266
 Tumorectomy 2 (2.2%) 0 2 (2.2%)  
 Tumor removed with at least one organ, but not compartmental resection 45 (50.6%) 19 (21.3%) 26 (29.2%)  
 Compartmental resection 42 (47.2%) 22 (24.7%) 20 (22.5%)  
Complication rate     0.214
 Clavien-Dindo 3a 7 (7.9%) 4 (9.8%) 3 (6.3%)  
 Clavien-Dindo 3b 9 (10.1%) 5 (12.2%) 4 (8.3%)  
 Clavien-Dindo 4a 3 (3.4%) 1 (2.4%) 2 (4.2%)  
 Clavien-Dindo 4b 3 (3.4%) 0 3 (6.3%)  
 Clavien-Dindo 5 (90 days) 5 (5.6%) 0 5 (10.4%)  
Median hospital stay after surgery (days) 22.0 (range 2–102) 23.0 (range 10–77) 21.0 (range 2–102) 0.952
Median ICU stay (days) 8.0 (range 0–55) 9.0 (range 4–22) 7.5 (range 0–55) 0.939
  1. ASA American Society of Anesthesiologists classification, FNCLCC Fédération Nationale des Centres de Lutte Contre Le Cancer, AJCC American Joint Committee on Cancer, ICU intensive care unit